All In Biotech

Investigational drug · Phase 2

INO-5401

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma, Urothelial Carcinoma.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

3

Any phase or sponsor naming "INO-5401"

First trial start

2018

May 31, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "INO-5401", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Glioblastoma
  • Urothelial Carcinoma

Approved drugs for the same conditions: Bladder and urothelial cancer · Brain tumors (glioma) · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "INO-5401" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Glioblastoma

  • Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms

  • L19TNFL19IL2, OnfekafuspPhase 310 trials

    Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III

  • VebreltinibPLB1001Phase 36 trials

    Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer

  • VRT106Phase 33 trials

    Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC

  • INO-9012Phase 24 trials

    Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma

  • AL58805Phase 22 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • AzeliragonPhase 22 trials

    Cantex Pharmaceuticals · Glioblastoma

  • MT-125Phase 22 trials

    Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.